Trial
NCT03519256
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Urinary Bladder Neoplasms
Intervention
Nivolumab
Why stopped
Insufficient Enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-01